Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients
详细信息 查看全文
- 作者：Muriel X.G. Drahta ; Kim M. Smitsa ; b ; Benjamin Tournierc ; Valerie Joosted ; Caroline Chapusotc ; Beatriz Carvalhoe ; Arjen H.G. Clevena ; Sarah Derksf ; Kim A.D. Woutersa ; Eric J.T. Beltg ; Hein B.A.C. Stockmannh ; Herman Brili ; Matty P. Weijenbergj ; Piet A. van den Brandtj ; Adriaan P. de Bruï ; nea ; James G. Hermank ; Gerrit A. Meijere ; Franç ; oise Piardc ; Veerle Melottea ; Manon van Engelanda ; manon.van.engeland@mumc.nl" class="auth_mail
- 关键词：REarranged during transfection (RET) ; DNA methylation ; Methylation marker ; Prognostic biomarker ; Colon cancer ; Colorectal cancer
- 刊名：Molecular Oncology
- 出版年：May 2014
- 年：2014
- 卷：8
- 期：3
- 页码：679-688
- 全文大小：1095 K
文摘
- •
RET methylation predicts poor prognosis for TNM stage II colorectal cancer patients.
- •
The poor prognosis in stage II patients is independent of MSI, CIMP and BRAF status.
- •
RET methylation can be detected by MSP and pyrosequencing.
- •
RET methylation can be detected in fresh-frozen and FFPE tissue.
- •
RET methylation may serve as a robust biomarker in clinical practice.